Extrapyramidal motor side-effects of firstand second-generation antipsychotic drugs

British Journal of Psychiatry

Volumn 200, Issue 5, 2012, Pages 387-392

  Peluso, Michael J ^a   Lewis, Shôn W ^b   Barnes, Thomas R E ^c   Jones, Peter B ^d  

^a YALE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c IMPERIAL COLLEGE LONDON   (United Kingdom)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

AMISULPRIDE; CHLORPROMAZINE; CHOLINERGIC RECEPTOR BLOCKING AGENT; DROPERIDOL; FLUPENTIXOL; FLUPENTIXOL DECANOATE; FLUPHENAZINE DECANOATE; HALOPERIDOL; HALOPERIDOL DECANOATE; LOXAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PIPOTIAZINE PALMITATE; QUETIAPINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; ZUCLOPENTHIXOL; ZUCLOPENTHIXOL DECANOATE;

ADULT; AGED; AKATHISIA; ARTICLE; DELUSIONAL DISORDER; DRUG EFFICACY; EXTRAPYRAMIDAL SYMPTOM; HUMAN; MAJOR CLINICAL STUDY; METABOLIC DISORDER; OUTCOME ASSESSMENT; PARKINSONISM; PRESCRIPTION; PROGNOSIS; PSYCHIATRIST; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SCHIZOPHRENIFORM DISORDER; TARDIVE DYSKINESIA;

ADOLESCENT; ADULT; AGED; AKATHISIA, DRUG-INDUCED; ANTIPSYCHOTIC AGENTS; BASAL GANGLIA DISEASES; CHOLINERGIC ANTAGONISTS; DYSKINESIA, DRUG-INDUCED; HUMANS; MIDDLE AGED; PARKINSONIAN DISORDERS; PROGNOSIS; PSYCHOTIC DISORDERS; SCHIZOPHRENIA, PARANOID; YOUNG ADULT;

EID: 84860584750     PISSN: 00071250     EISSN: 14721465     Source Type: Journal    
DOI: 10.1192/bjp.bp.111.101485     Document Type: Article

References (36)

1. Arvanitis LA, Miller BG. Multiple fixed doses of 'Seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: comparison with haloperidol and placebo. The Seroquel Trial 13 Study Group. Biol Psychiatry 1997; 42: 233-46. (Pubitemid 27325811)
2. Daniel DG, Zimbroff DL, Potkin SG, Reeves KR, Harrigan EP, Lakshminarayanan M. Ziprasidone 80 mg/day and 160 mg/day in the acute exacerbation of schizophrenia and schizoaffective disorder: a 6-week placebo-controlled trial. Ziprasidone Study Group. Neuropsychopharmacology 1999; 20: 491-505. (Pubitemid 29123876)
3. Kane JM, Woerner M, Lieberman J. Prevalence, incidence, and risk factors. J Clin Psychopharmacol 1988; 8 (suppl): 52-6.
4. Marder SR, Meibach RC. Risperidone in the treatment of schizophrenia. Am J Psychiatry 1994; 151: 825-35.
5. Potkin SG, Saha AR, Kujawa MJ, Carson WH, Ali M, Stock E, et al. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 2003; 60: 681-90. (Pubitemid 36818630)
6. Tollefson GD, Sanger TM. Negative symptoms: a path analytic approach to a double-blind, placebo- and haloperidol-controlled clinical trial with olanzapine. Am J Psychiatry 1997; 154: 466-74. (Pubitemid 27147598)
7. Gebhardt S, Hartling F, Hanke M, Mittendorf M, Theisen FM, Wolf-Ostermann K, et al. Prevalence of movement disorders in adolescent patients with schizophrenia and in relationship to predominantly atypical antipsychotic treatment. Eur Child Adolesc Psychiatry 2006; 15: 371-82. (Pubitemid 44571709)
8. Caroff SN, Mann SC, Campbell EC, Sullivan KA. Movement disorders associated with atypical antipsychotic drugs. J Clin Psychiatry 2002; 63 (suppl 4): 12-9. (Pubitemid 34242106)
9. Conner DE, Fletcher KE, Wood JS. Neuroleptic-related dyskinesias in children and adolescents. J Clin Psychiatry 2001; 62: 967-74. (Pubitemid 34007963)
10. Glazer WM. Extrapyramidal side effects, tardive dyskinesia, and the concept of atypicality. J Psychiatry 2000; 61: 16-21. (Pubitemid 30155229)
11. Kane JM. Tardive dyskinesia rates with atypical antipsychotics in adults: prevalence and incidence. J Clin Psychiatry 2004; 65 (suppl 9): 16-20.
12. Jones PB, Barnes TR, Davies L, Dunn G, Lloyd H, Hayhurst KP, et al. Randomized controlled trial of the effect on quality of life of second- vs first-generation antipsychotic drugs in schizophrenia: Cost Utility of the Latest Antipsychotic Drugs in Schizophrenia Study (CUtLASS 1). Arch Gen Psychiatry 2006; 63: 1079-87. (Pubitemid 44498387)
13. Rosenheck R, Perlick D, Bingham S, Liu-Mares W, Collins J, Warren S, et al. Effectiveness and cost of olanzapine and haloperidol in the treatment of schizophrenia: a randomized controlled trial. JAMA 2003; 290: 2693-702. (Pubitemid 37475597)
14. Leucht S, Wahlbeck K, Hamann J, Kissling W. New generation antipsychotics versus low-potency conventional antipsychotics: a systematic review and meta-analysis. Lancet 2003; 361: 1581-9. (Pubitemid 36578993)
15. Rochon PA, Stukel TA, Sykora K, Gill S, Garfinkel S, Anderson GM, et al. Atypical antipsychotics and parkinsonism. Arch Intern Med 2006; 165: 1882-8. (Pubitemid 41352083)
16. Fleischhacker WW. Second generation antipsychotics. Psychopharmacology (Berl) 2002; 162: 90-1.
17. Barnes TR. Evidence-based guidelines for the pharmacological treatment of schizophrenia: recommendations from the British Association for Psychopharmacology. J Psychopharmacol 2011; 25: 567-620.
18. Verdoux H, Tournier M, Bégaud B. Antipsychotic prescribing trends: a review of pharmaco-epidemiological studies. Acta Psychiatr Scand 2010; 121: 4-10.
19. Lieberman JA, Stroup TS, McEvoy JP, Swartz MS, Rosenheck RA, Perkins DO, et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353: 1209-23. (Pubitemid 41345943)
20. Miller DD, Caroff SN, Davis SM, Rosenheck RA, McEvoy JP, Saltz BL, et al. Extrapyramidal side-effects of antipsychotics in a randomised trial. Br J Psychiatry 2008; 193: 279-88.
21. Hugenholtz GW, Heerdink ER, Stolker JJ, Meijer WE, Egberts AC, Nolen WA. Haloperidol dose when used as active comparator in randomized controlled trials with atypical antipsychotics in schizophrenia: comparison with officially recommended doses. J Clin Psychiatry 2006; 67: 897-903. (Pubitemid 44049088)
22. Geddes J, Freemantle N, Harrison P, Bebbington P. Atypical antipsychotics in the treatment of schizophrenia: systematic overview and meta-regression analysis. BMJ 2000; 32: 1371-6.
23. Lewis SW, Davies L, Jones PB, Barnes TRE, Murray RM, Kerwin R, et al. Randomised controlled trials of conventional antipsychotic versus new atypical drugs, and new atypical drugs versus clozapine, in people with schizophrenia responding poorly to, or intolerant of, current drug treatment. Health Technol Assess 2006; 10: 1-83.
24. Henrichs DW, Hanlon TE, Carpenter WT. The Quality of Life Scale: an instrument for rating the schizophrenic deficit syndrome. Schizophr Bull 1984; 10: 388-98.
25. Barnes TR. The Barnes Akathisia Rating Scale: revisited. J Psychopharmacol 2003; 17: 365-70. (Pubitemid 38076330)
26. Simpson G, Angus JSW. A rating scale for extrapyramidal side effects. Acta Psychiatr Scand Suppl 1970; 212: 9-11.
27. Guy W. ECDEU Assessment Manual for Psychopharmacology. Revised DHEW Pub. (ADM). National Institute for Mental Health, 1976.
28. Last JM. A Dictionary of Epidemiology (4th edn). Oxford University Press, 2001.
29. Klawans HL, Rubovits R. Effect of cholinergic and anticholinergic agents on tardive dyskinesia. J Neurol Neurosurg Psychiatry 1974; 37: 941-7.
30. Greil W, Haag H, Rossnagl G, Rüther E. Effect of anticholinergics on tardive dyskinesia. A controlled discontinuation study. Br J Psychiatry 1984; 145: 304-10. (Pubitemid 14066482)
31. Moore NA, Tye NC, Axton MS, Risius FC. The behavioral pharmacology of olanzapine, a novel 'atypical' antipsychotic agent. J Pharmacol Exp Ther 1992; 262: 545-51.
32. Lloyd HM, Markwick AJ, Page ER, Lewis S, Barnes TRE. Attitudes to atypical and conventional antipsychotic drug treatment in clinicians participating in the CUtLASS study. Int J Psychiatry Clin Pract 2005; 9: 35-40. (Pubitemid 40363640)
33. Ren XS, Huang YH, Lee AF, Miller DR, Qian S, Kazis L. Adjunctive use of atypical antipsychotics and anticholinergic drugs among patients with schizophrenia. J Clin Pharm Ther 2005; 30: 65-71. (Pubitemid 41602093)
34. Rosenheck RA. Open forum: effectiveness versus efficacy of second-generation antipsychotics: haloperidol without anticholinergics as a comparator. Psychiatr Serv 2005; 56: 85-92. (Pubitemid 40094476)
35. Cheng F, Jones PB. Second-generation atypical versus first-generation conventional antipsychotic drug treatment in schizophrenia: another triumph of hope over experience? In Therapeutic Strategies in Schizophrenia (eds A Mortimer, PJ McKenna): 193-206. Clinical Publishing, 2010.
36. Mackin P, Thomas SH. Atypical antipsychotic drugs. BMJ 2011; 342: d1126.